Recap: Republic Bancorp Q2 Earnings

  Republic Bancorp (NASDAQ:RBCAA) reported its Q2 earnings results on Friday, July 22, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

 

Republic Bancorp (NASDAQ:RBCAA) reported its Q2 earnings results on Friday, July 22, 2022 at 08:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Republic Bancorp beat estimated earnings by 9.09%, reporting an EPS of $1.2 versus an estimate of $1.1.

Revenue was up $1.59 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.19 which was followed by a 0.41% drop in the share price the next day.

Here’s a look at Republic Bancorp’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 1.21 0.80 0.90 1.11
EPS Actual 1.40 0.84 0.99 1.16
Revenue Estimate 63.30M 45.78M 50.40M 55.17M
Revenue Actual 62.61M 50.34M 52.31M 49.64M

Listen to the earnings announcement yourself by clicking here.

To track all earnings releases for Republic Bancorp visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

HUTCHMED Announced License To Takeda To Develop And Commercialize Fruquintinib Outside China; Hutchmed To Receive $400M Upfront On Deal Closing; Up To 730M In Potential Future Milestone Payments Plus Royalties On Net Sales

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufacture of fruquintinib outside of mainland China, Hong Kong and Macau, where it is market

HCM